Show simple item record

dc.contributor.authorXu, Shuoyu
dc.contributor.authorWang, Yan
dc.contributor.authorTai, Dean C.S.
dc.contributor.authorWang, Shi
dc.contributor.authorCheng, Chee Leong
dc.contributor.authorPeng, Qiwen
dc.contributor.authorYan, Jie
dc.contributor.authorChen, Yongpeng
dc.contributor.authorSun, Jian
dc.contributor.authorLiang, Xieer
dc.contributor.authorZhu, Youfu
dc.contributor.authorWelsch, Roy E.
dc.contributor.authorWee, Aileen
dc.contributor.authorHou, Jinlin
dc.contributor.authorYu, Hanry
dc.contributor.authorRajapakse, Jagath
dc.contributor.authorSo, Peter T. C.
dc.date.accessioned2014-06-30T18:42:05Z
dc.date.available2014-06-30T18:42:05Z
dc.date.issued2014-02
dc.date.submitted2014-02
dc.identifier.issn01688278
dc.identifier.urihttp://hdl.handle.net/1721.1/88148
dc.description.abstractBackground & Aims: There is increasing need for accurate assessment of liver fibrosis/cirrhosis. We aimed to develop qFibrosis, a fully-automated assessment method combining quantification of histopathological architectural features, to address unmet needs in core biopsy evaluation of fibrosis in chronic hepatitis B (CHB) patients. Methods: qFibrosis was established as a combined index based on 87 parameters of architectural features. Images acquired from 25 Thioacetamide-treated rat samples and 162 CHB core biopsies were used to train and test qFibrosis and to demonstrate its reproducibility. qFibrosis scoring was analyzed employing Metavir and Ishak fibrosis staging as standard references, and collagen proportionate area (CPA) measurement for comparison. Results: qFibrosis faithfully and reliably recapitulates Metavir fibrosis scores, as it can identify differences between all stages in both animal samples (p <0.001) and human biopsies (p <0.05). It is robust to sampling size, allowing for discrimination of different stages in samples of different sizes (area under the curve (AUC): 0.93–0.99 for animal samples: 1–16 mm[superscript 2]; AUC: 0.84–0.97 for biopsies: 10–44 mm in length). qFibrosis can significantly predict staging underestimation in suboptimal biopsies (<15 mm) and under- and over-scoring by different pathologists (p <0.001). qFibrosis can also differentiate between Ishak stages 5 and 6 (AUC: 0.73, p = 0.008), suggesting the possibility of monitoring intra-stage cirrhosis changes. Best of all, qFibrosis demonstrates superior performance to CPA on all counts. Conclusions: qFibrosis can improve fibrosis scoring accuracy and throughput, thus allowing for reproducible and reliable analysis of efficacies of anti-fibrotic therapies in clinical research and practice.en_US
dc.description.sponsorshipJanssen Pharmaceutical Ltd.en_US
dc.description.sponsorshipSingapore-MIT Alliance for Research and Technologyen_US
dc.language.isoen_US
dc.publisherElsevieren_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/j.jhep.2014.02.015en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourceElsevier Open Accessen_US
dc.titleqFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patientsen_US
dc.typeArticleen_US
dc.identifier.citationXu, Shuoyu, Yan Wang, Dean C.S. Tai, Shi Wang, Chee Leong Cheng, Qiwen Peng, Jie Yan, et al. “qFibrosis: A Fully-Quantitative Innovative Method Incorporating Histological Features to Facilitate Accurate Fibrosis Scoring in Animal Model and Chronic Hepatitis B Patients.” Journal of Hepatology (February 2014). © 2014 European Association for the Study of the Liveren_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Mechanical Engineeringen_US
dc.contributor.departmentSloan School of Managementen_US
dc.contributor.mitauthorRajapakse, Jagathen_US
dc.contributor.mitauthorWelsch, Roy E.en_US
dc.contributor.mitauthorSo, Peter T. C.en_US
dc.contributor.mitauthorYu, Hanryen_US
dc.relation.journalJournal of Hepatologyen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsXu, Shuoyu; Wang, Yan; Tai, Dean C.S.; Wang, Shi; Cheng, Chee Leong; Peng, Qiwen; Yan, Jie; Chen, Yongpeng; Sun, Jian; Liang, Xieer; Zhu, Youfu; Rajapakse, Jagath C.; Welsch, Roy E.; So, Peter T.C.; Wee, Aileen; Hou, Jinlin; Yu, Hanryen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-0339-3685
dc.identifier.orcidhttps://orcid.org/0000-0002-9038-1622
dc.identifier.orcidhttps://orcid.org/0000-0003-4698-6488
mit.licensePUBLISHER_POLICYen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record